Clinical Trials Directory

Trials / Recruiting

RecruitingNCT05611034

In Vivo Lung Perfusion (IVLP) for Colorectal Cancer Metastatic to Lung

In Vivo Lung Perfusion (IVLP) as an Adjuvant Treatment for Patients With Resectable Pulmonary Metastases of Colorectal Cancers

Status
Recruiting
Phase
Phase 1
Study type
Interventional
Enrollment
10 (estimated)
Sponsor
University Health Network, Toronto · Academic / Other
Sex
All
Age
18 Years – 70 Years
Healthy volunteers
Not accepted

Summary

This study is investigating a new technique for delivering chemotherapy directly into the lungs at the time of surgery. Delivering chemotherapy directly to the lungs could potentially kill any microscopic cancer cells that are present in the lungs at the time of surgery, while sparing other major organs in the body from the side effects of chemotherapy. This technique is called In Vivo Lung Perfusion (IVLP). At the University Health Network, this IVLP technique has been used recently in a Phase I study in patients with sarcoma, and we are now expanding on that experience to include patients with colorectal metastases. The purpose of this study is to test the safety of the IVLP technique and find the dose that seems right in humans. Participants are given oxaliplatin into one lung via IVLP and are watched very closely to see what side effects they have and to make sure the side effects are not severe. If the side effects are not severe, then more participants are asked to join the study and are given a higher dose of oxaliplatin. Participants joining the study later on will get higher doses of oxaliplatin than participants who join earlier. This will continue until a dose is found that causes severe but temporary side effects. Doses higher than that will not be given. The other lung will not be infused with anything, so that we can limit unforeseen toxicity to a single lung and see if one lung does better than the other.

Conditions

Interventions

TypeNameDescription
DRUGOxaliplatinOxaliplatin infusion in single lung via IVLP technique

Timeline

Start date
2023-02-06
Primary completion
2026-01-01
Completion
2032-01-01
First posted
2022-11-09
Last updated
2025-06-25

Locations

1 site across 1 country: Canada

Source: ClinicalTrials.gov record NCT05611034. Inclusion in this directory is not an endorsement.